Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

More women discontinue antihypertensive treatment than men

14 Jan 2020

More women than men cease from taking their antihypertensive medication, as shown by the results of a recent study conducted in a real-life setting.

The investigators sought to compare persistence with antihypertensive drug therapy between men and women in a large cohort of patients. They identified a total of 60,526 residents of the Italian Lombardy Region, who were aged 40–80 years and newly treated with antihypertensive drugs during 2010, and followed them for 1 year after the first prescription.

Treatment discontinuation was defined as lack of prescription renewal for at least 90 days. The risk ratio of treatment discontinuation in relation to sex was estimated by fitting log-binomial regression models. Analyses were stratified according to age, comorbidity status and the initial antihypertensive treatment strategy.

Of the participants, 37 percent discontinued antihypertensive treatment during follow-up. The risk of treatment discontinuation was 10-percent (95 percent confidence interval, 8–12) lower in men than in women. In addition, men showed better adherence to antihypertensive treatment than women, and this was true in both younger (40–64 years) and older patients (65–80 years), in patients starting treatment with any major antihypertensive drug, and in patients with a low comorbidity status.

However, no evidence was found on whether men and women had a different risk of treatment discontinuation when their comorbidity status was worse or initial antihypertensive treatment was based on drug combinations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.